Skip to main content
SpringerLink
Log in

Rituximab maintenance therapy in follicular lymphoma

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Follicular lymphomas are considered incurable, but most patients survive for many years. The introduction of rituximab into the treatment of malignant lymphomas of the B-cell lineage has had a major impact on the management of these diseases. Numerous studies confirm the benefit of rituximab, in monotherapy and in combination with chemotherapy, in regard to remission rate, remission duration, and overall survival. To further improve the treatment results, rituximab has been applied as maintenance therapy after induction with rituximab alone or with immunochemotherapy including rituximab. This article reviews the trials that have incorporated rituximab maintenance in the treatment of patients with follicular lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993, 20:75–88.

    PubMed  CAS  Google Scholar 

  2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833.

    PubMed  CAS  Google Scholar 

  3. Hainsworth JD, Litchy S, Burris HA 3rd, et al.: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 2002, 20:4261–4267.

    Article  PubMed  CAS  Google Scholar 

  4. Colombat P, Brousse N, Morschhauser F, Franchi-Rezgui P: Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended follow-up (F/Up) of 7 years [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 486.

  5. Ghielmini M, Schmitz SF, Cogliatti SB, et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004, 103:4416–4423.

    Article  PubMed  CAS  Google Scholar 

  6. Forstpointner R, Dreyling M, Repp R, et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064–3071.

    Article  PubMed  CAS  Google Scholar 

  7. Hiddemann W, Kneba M, Dreyling M, et al.: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725–3732.

    Article  PubMed  CAS  Google Scholar 

  8. Marcus R, Imrie K, Belch A, et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005, 105:1417–1423.

    Article  PubMed  CAS  Google Scholar 

  9. Herold M, Haas A, Srock S, et al.: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007, 25:1986–1992.

    Article  PubMed  CAS  Google Scholar 

  10. Foussard C, Mounier N, Van Hoof A, et al.: Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma (FL) patients (pts) [abstract]. Proc Am Soc Clin Oncol 2006, 24:424s (Abstract 7508).

    Google Scholar 

  11. van Oers MH, Klasa R, Marcus RE, et al.: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295–3301.

    Article  PubMed  Google Scholar 

  12. Davis TA, Grillo-Lopez AJ, White CA, et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000, 18:3135–3143.

    PubMed  CAS  Google Scholar 

  13. Berinstein NL, Grillo-Lopez AJ, White CA, et al.: Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998, 9:995–1001.

    Article  PubMed  CAS  Google Scholar 

  14. Hainsworth JD, Litchy S, Shaffer DW, et al.: Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma—a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005, 23:1088–1095.

    Article  PubMed  CAS  Google Scholar 

  15. Gordan LN, Grow WB, Pusateri A, et al.: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol 2005, 23:1096–1102.

    Article  PubMed  CAS  Google Scholar 

  16. Ghielmini M, Rufibach K, Salles G, et al.: Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005, 16:1675–1682.

    Article  PubMed  CAS  Google Scholar 

  17. Piro LD, White CA, Grillo-Lopez AJ, et al.: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1999, 10:655–661.

    Article  PubMed  CAS  Google Scholar 

  18. Hochster H, Weller E, Gascoyne RD, et al.: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 349.

  19. Forstpointner R, Unterhalt M, Dreyling M, et al.: Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003–4008.

    Article  PubMed  CAS  Google Scholar 

  20. Dreyling M, Forstpointner R, Boeck H-P, et al.: Combined immuno-chemotherapy followed by rituximab maintenance is an effective salvage treatment after prior rituximab containing therapy: results of a GLSG-subgroup analysis in patients with relapsed indolent lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 2769.

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine III, University of Munich, Grosshadern, Marchioninistrasse 15, 81377, München, Germany

    Martin Dreyling

Authors
  1. Roswitha Forstpointner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Dreyling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Dreyling.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forstpointner, R., Dreyling, M. Rituximab maintenance therapy in follicular lymphoma. Curr Hematol Malig Rep 2, 213–218 (2007). https://doi.org/10.1007/s11899-007-0029-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-007-0029-8

Keywords

Search

Navigation